Results 111 to 120 of about 8,906 (137)

Neuroendocrinology meets addiction: Emerging pharmacotherapies on the horizon. [PDF]

J Intern Med
Loften A, Farokhnia M, Vendruscolo LF, Leggio L.   +3 more
europepmc   +1 more source

The Role of Mifepristone in Cervical Maturation and Induction of Labor: A Narrative Review of the Literature. [PDF]

J Clin Med
Toscano FP, D'Angelo M, Giorno A, Gallo A, Piccolo M, Saccone G, Mollo A, Laurelli G.   +7 more
europepmc   +1 more source

Acceptability of misoprostol-only medication abortion dispensed by mail-order or retail pharmacy: a qualitative study based on in-depth interviews in the United States. [PDF]

Sex Reprod Health Matters
Johnson DM, Ramaswamy S, Gomperts R.
europepmc   +1 more source

Carboplatin, gemcitabine, and mifepristone for advanced breast and recurrent/persistent epithelial ovarian cancer. [PDF]

Breast Cancer Res Treat
Stringer-Reasor EM, Saha P, Kocherginsky M, Lastra R, Baker G, Lenygel E, Karrison T, Olalde L, Mokrzycki E, Hahn OM, Hoffman PC, Conzen SD, Fleming GF, Nanda R.   +13 more
europepmc   +1 more source

Exosomal Gene Biomarkers in Osteosarcoma: Mifepristone as a Targeted Therapeutic Revealed by Multi-Omics Analysis. [PDF]

FASEB J
Li Z, Guo J, Zhu S, Zou Y, Ma W, Niu J, Liu R, Zhao K.   +7 more
europepmc   +1 more source

Expanding contraceptive options: A scoping review of medically approved contraceptive methods that are not in the WHO Medical Eligibility Criteria.

Contraception
Mokkarala S, Kamuyango A, Kiarie J, Kidula N, Jiang L, Sonalkar S.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Mifepristone

Annals of Pharmacotherapy, 2001
OBJECTIVE: To review the efficacy and safety of mifepristone (with misoprostol) for the termination of early pregnancy. DATA SOURCES: A MEDLINE search (1966–October 2000) was conducted, and additional references listed in articles were included; unpublished data obtained from the manufacturer were used to identify data from the scientific literature ...
R M, DeHart, M S, Morehead
openaire   +3 more sources

Mifepristone

Reactions Weekly, 2023
  +6 more sources

Mifepristone: Antineoplastic Studies

Clinical Obstetrics and Gynecology, 1996
Emerging research suggests that mifepristone may have significant clinical applications in the treatment of certain neoplastic disorders. For example in vitro studies have shown that RU-486 can inhibit or stimulate--depending on the cell line and the hormonal milieu of the culture medium--the growth of breast cancer cells. In hormone-sensitive breast
O, Sartor, W D, Figg
openaire   +2 more sources

Mifepristone

Reactions Weekly, 2016
  +7 more sources